| Expression pattern: |
DN |
| Associated gene: |
- |
| Associated microRNA: |
hsa-miR-182-5p, hsa-miR-615-3p |
| Biological function: |
Significantly down-regulated in PBMCs of patients with nAMD; included in the cuproptosis-related circRNA-miRNA-mRNA network, but no specific functional assay was reported. |
| Molecular mechanism: |
Predicted ceRNA-related regulatory network with miRNA interactions; no experimentally validated mechanism specific to circTKT was reported. |
| Biological pathway or process: |
ceRNA regulation (other); other pathway/process (other) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; Clinical Sample Validation; Bioinformatics Analysis; In Vivo Animal Model |
| Clinical significance: |
Potential target and biomarker for nAMD prevention and treatment as part of the identified cuproptosis-related non-coding RNA network. |
| Description: |
circTKT was significantly down-regulated in PBMC samples from patients with nAMD. It was included in the cuproptosis-related circRNA-miRNA-mRNA network, although the paper did not define a circTKT-specific validated molecular mechanism. |
| Confidence score: |
0.4997 |